Scott Ribich,
Associate Director
Dr. Ribich is an Associate Director in the Biological Sciences Department at Epizyme, a clinical stage biopharmaceutical company that creates novel epigenetic therapies for cancer patients. Dr. Ribich received his BS in Biology from MIT, and his Ph.D in Biochemistry from Harvard University in 2005 in the laboratory of Professor Thomas Maniatis. He completed his postdoctoral training at Brigham and Women’s Hospital in 2008 with Professor Antonio Bianco. Both his graduate and postgraduate work focused on the molecular biology and epigenetics underlying disease and development. In 2008, he joined Sirtris, a GlaxoSmithKline company, which developed metabolic disease therapeutics targeting the sirtuin family of deacteylases. He has worked at Epizyme since 2011, where his group focuses on the role of the histone methyltransferase EZH2 in various oncology indications.
|
|
|
